Antibody drug target identified for influenza viruses
Researchers have found a small subset of antibodies that target a site at the base of the influenza virus hemagglutinin protein.
List view / Grid view
Researchers have found a small subset of antibodies that target a site at the base of the influenza virus hemagglutinin protein.
The new study identified PDZ-binding kinase (PBK) as a promising target for pulmonary hypertension and assessed two PBK inhibitors.
Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.
Professors Piergiorgio Percipalle and Gennaro Esposito summarise their study which revealed two nanobodies that could inhibit a non-structural protein of SARS-CoV-2.
The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
This issue includes articles that discuss the development of long-term 3D tissue cultures from human biopsy samples, the application of flow cytometry in drug discovery and automation for upstream processing in a biologics manufacturing environment. Also included are features on informatics, proteomics and CRISPR.
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
Verubecestat demonstrated poor results in Alzheimer's trials, but helped suppress tumours in pre-clinical glioblastoma models.
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
With an ever-increasing emphasis on minimising drug candidate attrition, scientists are focusing on target safety at earlier points in the research process. In this exclusive interview, Drug Target Review spoke with Dr Gordon Baxter, Chief Scientific Officer of Instem, to learn how target safety assessments can enable researchers to quickly…
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.